Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 7;7(6):1364-1376.
doi: 10.1016/j.ekir.2022.03.035. eCollection 2022 Jun.

Vasopressin for Post-kidney Transplant Hypotension

Muhammad Y Jan  1 , Sharon M Moe  1   2 , Oluwafisayo Adebiyi  1 , Jeannie Chen  3 , John Powelson  4 , Heather N Burney  5 , Muhammad S Yaqub  1 , Dennis P Mishler  1 , Ranjani N Moorthi  1 , Tim E Taber  1 , Melissa D Anderson  1 , Yang Li  5 , Xiaochun Li  5 , Jonathan A Fridell  4 , William C Goggins  4 , Asif A Sharfuddin  1
Affiliations

Vasopressin for Post-kidney Transplant Hypotension

Muhammad Y Jan et al. Kidney Int Rep. .

Abstract

Introduction: Hypotension after deceased donor kidney transplant (DDKT) is a risk factor for delayed graft function (DGF) and poor graft survival (GS). We hypothesize that vasopressin use in hypotensive DDKT recipients (DDKTRs) to increase blood pressure (BP) reduces DGF rates and is safe without increasing mortality.

Methods: Group with vasopressin "study group" (n = 45) was defined as DDKTRs between 2012 and 2017 who required vasopressin for hypotension systolic BP (SBP) <120 mm Hg or diastolic BP (DBP) <60 mm Hg. DDKTRs with no-vasopressin "comparison group" (n = 90) were propensity score-matched DDKTRs between 2012 and 2017 without vasopressin use. Primary outcomes were GS, creatinine and allograft biopsy rate at 1 year, DGF rate, and death during transplant hospitalization.

Results: Vasopressin group had lower mean maximum and minimum SBP and DBP in the operating room (OR). Median vasopressin start time post-DDKT was 2 hours (interquartile range [IQR] 1-6), and duration of use was 42 hours (IQR 24-63). DGF, creatinine at 1 year, and allograft biopsy rates were comparable. No deaths occurred during transplant hospitalization. Multivariable analysis did not find an effect of vasopressin use on GS.

Conclusion: Treatment of hypotensive DDKTRs with vasopressin is safe and facilitated similar graft function and survival with that of nonhypotensive patients. In the absence of a randomized control trial, our study supports the safety of vasopressin therapy to prevent the adverse effects of hypotension.

Keywords: deceased donor kidney transplant; delayed graft function; graft survival; vasopressin.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Study diagram, selection of study group, comparison group, inclusion and exclusion criteria. DBP, diastolic blood pressure; DDKTR, deceased donor kidney transplant recipient; KT, kidney transplantation; SBP, systolic blood pressure.
Figure 2
Figure 2
Comparison of vasopressin group (study group) and no-vasopressin group (comparison group): propensity-matched groups. BMI, body mass index; DBD, brain dead donor; DCD, donation after cardiac death; DM, diabetes mellitus; ESKD, end-stage kidney disease.
Figure 3
Figure 3
Comparison of overall graft survival between vasopressin group versus no-vasopressin group. KGS, kidney graft survival; KM, Kaplan-Meier; NE, not estimable (the survival curve did not cross 0.5).
Figure 4
Figure 4
Comparison of death-censored kidney graft survival between vasopressin group versus no-vasopressin group. KGS, kidney graft survival; KM, Kaplan-Meier; NE, not estimable (the survival curve did not cross 0.5).
Figure 5
Figure 5
Comparison of overall patient survival between vasopressin group versus no-vasopressin group. KM, Kaplan-Meier; NE, not estimable (the survival curve did not cross 0.5).
See this image and copyright information in PMC

References

    1. Dolla C., Mella A., Vigilante G., et al. Recipient pre-existing chronic hypotension is associated with delayed graft function and inferior graft survival in kidney transplantation from elderly donors. PLoS One. 2021;16 doi: 10.1371/journal.pone.0249552. - DOI - PMC - PubMed
    1. Sandid M.S., Assi M.A., Hall S. Intraoperative hypotension and prolonged operative time as risk factors for slow graft function in kidney transplant recipients. Clin Transpl. 2006;20:762–768. doi: 10.1111/j.1399-0012.2006.00567.x. - DOI - PubMed
    1. Schnuelle P., Gottmann U., Hoeger S., et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009;302:1067–1075. doi: 10.1001/jama.2009.1310. - DOI - PubMed
    1. Zirpe K., Gurav S. Brain death and management of potential organ donor: an Indian perspective. Indian J Crit Care Med. 2019;23:S151–s156. doi: 10.5005/jp-journals-10071-23194. - DOI - PMC - PubMed
    1. Ciapetti M., di Valvasone S., di Filippo A., Cecchi A., Bonizzoli M., Peris A. Low-dose dopamine in kidney transplantation. Transplant Proc. 2009;41:4165–4168. doi: 10.1016/j.transproceed.2009.08.058. - DOI - PubMed

LinkOut - more resources